Benitec Biopharma jumps as FDA clears muscle disorder drug study

Benitec Biopharma

26/06/2023 17:12

** Benitec Biopharma Inc's shares  BNTC.O  more than double
to $0.40 
    ** Drug developer said U.S. FDA has cleared application to
initiate study of its experimental drug to treat Oculopharyngeal
Muscular Dystrophy-related Dysphagia (OPMD)
    ** OPMD is a genetic muscle disorder affecting muscles of
upper eyelids and throat. The disease affects a patients ability
to swallow
    ** Including session gains, stock more than doubles YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))